A phase 1/2a trial (NCT02650999), evaluating pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy, showed a best ORR of 25%. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.